|
KMID : 0032220190310020204
|
|
Annals of Dermatology
2019 Volume.31 No. 2 p.204 ~ p.208
|
|
|
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib
|
|
March-Rodriguez Alvaro
Bellosillo Beatriz
Alvarez-Larran Alberto
Besses Carles
Pujol Ramon M.
Toll Agusti
|
|
|
Abstract
|
|
|
|
Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72 year-old man patient with polycythemia vera who developed multiple cutaneous squamous cell carcinomas (cSCCs) with keratoacanthoma-like histological features while on treatment with ruxolitinib. Similar lesions have been reported in an isolated patient who also received ruxolitinib. Our case confirms that ruxolitinib may induce eruptive cSCCs with characteristic clinical and histological features that differentiate them from conventional non-drug induced lesions. Moreover, we performed a mutational panel analysis of the tumors. The lack of specific mutations in these tumors suggests an impairment of immunosurveillance in the origin of the cutaneous lesions. Frequent and thorough dermatological examinations in patients receiving ruxolitinib with a history of photodamage, skin cancer and/or previous hydroxyurea intake is thus recommended.
|
|
|
KEYWORD
|
|
|
Carcinoma, squamous cell, Janus kinase 1, Janus kinase 2, Keratoacanthoma, Polycythemia vera
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|